While elevated serum levels of GGT1 associated with liver and pancreatic cancers have been used as a diagnostic marker for monitoring disease progression and response to clinical intervention, its utility as a pre-symptomatic cancer biomarker has been hampered by the fact that high serum GGT1 levels are also observed in non-malignant diseases, ranging from alcoholic hepatitis to myocardial infarction [11-13]. This evidence concerns the gene GGT1 and cancer.